ANKMY2 Activators
ANKMY2 Activators are a diverse group of chemical compounds that enhance the functional activity of ANKMY2 by interacting with and influencing cellular pathways associated with vesicle trafficking and cytoskeletal dynamics. Forskolin, by increasing cAMP levels, and its analogs 8-Bromo-cAMP and Dibutyryl-cAMP, activate PKA, which in turn could phosphorylate proteins that regulate ANKMY2 activities, thereby enhancing its role in vesicle transport. Similarly, Ionomycin and A23187 (Calcimycin) raise intracellular Ca2+ concentrations, which could activate calmodulin-dependent kinases, subsequently influencing ANKMY2 function in vesicle trafficking. PMA, through its activation of PKC, might phosphorylate substrates that interact with ANKMY2, enhancing its functionality in the endocytic and secretory pathways. Moreover, the inhibition of protein phosphatases by CalyculinA and Okadaic acid could result in a net increase in protein phosphorylation, which may inadvertently upregulate ANKMY2 activity by affecting its binding dynamics or subcellular localization.
The activity of ANKMY2 is further influenced by compounds that modulate kinase activity, and thus indirectly affect the protein's function in vesicle formation and transport. Epigallocatechin gallate (EGCG), by inhibiting a range of kinases, may foster an environment conducive to ANKMY2 activation, possibly by affecting the protein's interaction with its partners. Brefeldin A disrupts Golgi apparatus function, potentially inducing mechanisms that compensate by enhancing ANKMY2's role in trafficking. N6-Benzoyladenosine, through adenylyl cyclase stimulation, raises cAMP levels similarly to Forskolin, leading to PKA activation and subsequent effects on ANKMY2. Furthermore, Lithium chloride's inhibition of GSK-3 might indirectly boost ANKMY2's involvement in GSK-3-associated vesicle transport pathways. Collectively, these ANKMY2 Activators, by targeting specific signaling molecules and pathways, facilitate the enhancement of ANKMY2-mediated functions, crucial for maintaining efficient vesicle formation, transport, and cytoskeleton-associated processes, without directly altering its expression or by acting as direct ligands.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate and thus increase the activity of ANKMY2, a protein involved in vesicle transport. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, elevating intracellular Ca2+ levels. The rise in intracellular calcium can activate calmodulin and other calcium-binding proteins that interact with ANKMY2, potentially enhancing its function in vesicle trafficking and cytoskeletal dynamics. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC) which can phosphorylate a range of substrates. PKC-mediated phosphorylation may lead to the activation of ANKMY2 by promoting its association with binding partners involved in vesicular transport. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. PKA can phosphorylate proteins in the vesicle trafficking pathway, potentially enhancing ANKMY2 activity in cargo sorting and transport. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, activating calcium/calmodulin-dependent protein kinases. These kinases could then influence ANKMY2 function by modifying its interaction with vesicle transport machinery. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is an inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases can result in increased phosphorylation levels of certain proteins, which may indirectly enhance the activity of ANKMY2 in its role in vesicular dynamics. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation of proteins within the cell. This could indirectly enhance ANKMY2's role in vesicle formation and transport. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol that can inhibit a variety of kinases. By modulating kinase activity, EGCG could create a favorable environment for the activation of ANKMY2 through altered protein-protein interactions in the vesicle trafficking pathways. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which could enhance the functional activity of ANKMY2 by inducing compensatory mechanisms in vesicle formation and trafficking. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase 3 (GSK-3). By inhibiting GSK-3, lithium may indirectly enhance ANKMY2 function through pathways that involve GSK-3-regulated vesicle transport processes. | ||||||